Insmed Incorporated (NASDAQ:INSM) Stock Holdings Decreased by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC lessened its position in Insmed Incorporated (NASDAQ:INSM) by 46.0% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 96,824 shares of the biopharmaceutical company’s stock after selling 82,508 shares during the quarter. Rice Hall James & Associates LLC’s holdings in Insmed were worth $6,487,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in INSM. EntryPoint Capital LLC acquired a new stake in Insmed during the 1st quarter valued at $33,000. Fidelis Capital Partners LLC acquired a new position in Insmed during the first quarter valued at $34,000. First Horizon Advisors Inc. lifted its stake in Insmed by 83.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 287 shares in the last quarter. Headlands Technologies LLC purchased a new position in Insmed during the 1st quarter valued at about $59,000. Finally, CWM LLC lifted its position in Insmed by 11.0% in the 2nd quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 155 shares in the last quarter.

Wall Street Analyst Weigh In

INSM has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $90.00 price target on shares of Insmed in a report on Thursday, August 29th. Stifel Nicolaus upped their target price on Insmed from $74.00 to $88.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Bank of America reaffirmed a “buy” rating and set a $83.00 price objective on shares of Insmed in a research report on Friday, July 5th. TD Cowen raised their target price on Insmed from $75.00 to $98.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, Mizuho upped their price target on Insmed from $36.00 to $82.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $79.19.

Insider Activity at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the completion of the transaction, the insider now owns 100,100 shares in the company, valued at $7,157,150. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.60% of the stock is currently owned by insiders.

Insmed Price Performance

Shares of INSM stock opened at $71.57 on Wednesday. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The company has a market capitalization of $12.30 billion, a P/E ratio of -13.68 and a beta of 1.11. The stock has a 50 day moving average of $73.96 and a two-hundred day moving average of $49.34. The company has a current ratio of 2.71, a quick ratio of 2.53 and a debt-to-equity ratio of 25.05.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The company had revenue of $90.34 million during the quarter, compared to analysts’ expectations of $87.95 million. Insmed’s revenue for the quarter was up 17.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.78) earnings per share. As a group, equities analysts expect that Insmed Incorporated will post -5.42 EPS for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.